会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 23. 发明授权
    • System and method for real time lip synchronization
    • 用于实时唇形同步的系统和方法
    • US07433490B2
    • 2008-10-07
    • US11435122
    • 2006-05-16
    • Ying HuangStephen Ssu-te LinBaining GuoHeung-Yeung Shum
    • Ying HuangStephen Ssu-te LinBaining GuoHeung-Yeung Shum
    • G06K9/00G10L15/00
    • G06K9/00335G10L2021/105
    • A novel method for synchronizing the lips of a sketched face to an input voice. The lip synchronization system and method approach is to use training video as much as possible when the input voice is similar to the training voice sequences. Initially, face sequences are clustered from video segments, then by making use of sub-sequence Hidden Markov Models, a correlation between speech signals and face shape sequences is built. From this re-use of video, the discontinuity between two consecutive output faces is decreased and accurate and realistic synthesized animations are obtained. The lip synchronization system and method can synthesize faces from input audio in real-time without noticeable delay. Since acoustic feature data calculated from audio is directly used to drive the system without considering its phonemic representation, the method can adapt to any kind of voice, language or sound.
    • 一种用于将草绘脸部的嘴唇同步到输入声音的新颖方法。 唇部同步系统和方法方法是当输入的声音类似于训练声音序列时尽可能多地使用训练视频。 最初,面部序列从视频片段聚类,然后通过利用子序列隐马尔可夫模型,构建了语音信号和面部形状序列之间的相关性。 从这种视频的再次使用,两个连续的输出面之间的不连续性被降低,并且获得准确而逼真的合成动画。 唇同步系统和方法可以实时地从输入音频合成面部,而没有明显的延迟。 由于从音频计算的声学特征数据直接用于驱动系统而不考虑其音位表示,该方法可以适应任何种类的语音,语言或声音。
    • 30. 发明申请
    • Substituted amide beta secretase inhibitors
    • 取代的酰胺β分泌酶抑制剂
    • US20060040994A1
    • 2006-02-23
    • US11185419
    • 2005-07-20
    • Ying HuangGuoqing LiAndrew Stamford
    • Ying HuangGuoqing LiAndrew Stamford
    • A61K31/4439A61K31/4178A61K31/4166C07D405/02C07D403/02
    • C07D401/12C07D241/04C07D241/08C07D401/10C07D403/12C07D405/12C07D413/12C07D417/12
    • Disclosed are novel compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, R4 and X are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease. Also disclosed are methods of treating a cognitive or neurodegenerative disease comprising administering to a patient I need of such treatment a combination of at least one compound of formula I and at least one compound selected from the group consisting of β-secretase inhibitors other than those of formula I, HMG-CoA reductase inhibitors, gamma-secretase inhibitors, non-steroidal anti-inflammatory agents, N-methyl-D-aspartate receptor antagonists, cholinesterase inhibitors and anti-amyloid antibodies.
    • 公开了下式的新化合物或其药学上可接受的盐或溶剂化物,其中R 1,R 2,R 3,R SUP > 4和X如说明书中所定义。 还公开了包含式I化合物的药物组合物。还公开了治疗认知或神经变性疾病如阿尔茨海默病的方法。 还公开了治疗认知或神经变性疾病的方法,其包括向需要这种治疗的患者施用至少一种式I化合物和至少一种选自β-分泌酶抑制剂的化合物的组合,所述β-分泌酶抑制剂除 式I,HMG-CoA还原酶抑制剂,γ-分泌酶抑制剂,非甾体抗炎剂,N-甲基-D-天冬氨酸受体拮抗剂,胆碱酯酶抑制剂和抗淀粉样蛋白抗体。